I’ve spent a lot of time looking into how we make medicines, and honestly, the shift toward biologics is nothing short of a miracle. But there’s a recurring “elephant in the room” that doesn’t get enough play in casual conversation: immunogenicity. It sounds like a mouthful, but it’s basically just the story of our bodies being a little too good
I remember sitting in a biology class years ago, looking at diagrams of simple chemical pills and thinking that was the peak of medicine. You take a tablet, it dissolves, and you feel better. But lately, the conversation has shifted toward something much more complex and, frankly, a lot more exciting. We’ve entered a phase where we aren’t just using
In the pharmaceutical world, “quality” is often treated as a buzzword. But for a patient relying on a life-saving medication, it is a literal requirement for survival. Whether you are dealing with traditional small-molecule drugs or complex therapeutic biological products, the manufacturing process is where a brand’s promise is either fulfilled or broken. Ensuring consistent quality isn’t about luck; it’s
If you’ve been following healthcare news lately, you’ve probably heard the term “biologics” popping up more and more. While standard medications—the kind you find in a typical pill bottle—are made through relatively straightforward chemical processes, biologics are in a league of their own. To put it simply: if a standard drug is like a simple bicycle, a biologic is more
Look, the whole healthcare world is moving, perpetually. And with that movement, the legal frameworks governing how we, as manufacturers, actually make and then get to market these therapeutic products are changing. The biggest change, the one you absolutely cannot ignore, is the Therapeutic Products Bill (TPB). It reconstructs, fundamentally, how every single natural health product (NHP) is now going
If you’ve ever wondered why some medicines feel almost magical in how targeted they are, chances are we’re talking about therapeutic biologics – complex drugs derived from living cells. From monoclonal antibodies to recombinant proteins, they tackle diseases in ways traditional drugs often can’t. But here’s the thing: these aren’t simple pills you can mass-produce without thought. Every batch is
Therapeutic biologicals – including monoclonal antibodies, recombinant proteins, biosimilars, and cell/gene therapies—represent the future of targeted healthcare. As the global pharmaceutical landscape shifts, India is well-positioned to play a pivotal role. But realizing this potential requires addressing key hurdles while leveraging strategic advantages. Manufacturing Complexity & Quality Assurance: Biological products are inherently complex, derived from living cells, and sensitive to
Windlas Biotech Limited: Pioneering Pharma Solutions Globally | Empowering Healthier Lives | Authenticity and Affordability Redefined
Copyright ©2024 Windlas. All Rights Reserved.
©2023 Windlas. All Rights Reserved.
Empowering innovation at Windlas Biotech – where advanced research meets sustainable solutions. Driven by science, we are dedicated to transforming health through pioneering biotech advancements and excellence in research and development.
